Karessa Pharma Holding AB announces today that a patent application for Vardenafil buccal film has been submitted to the European Patent Office
On the 20th of December 2017, Karessa submitted an application to the European Patent Office concerning the use and formulation of buccal film with Vardenafil.
Karessa develops effective pharmaceuticals based on our patented buccal film and proven pharmaceutical substances in the therapeutic area of erectile dysfunction. As a result of this work, Karessa has now been able to submit a patent application for the use and formulation of the buccal film with Vardenafil.
The patent application for the buccal film ("Film patent") was submitted in 2005 and the patent application has so far been approved in 14 markets (Sweden, the USA (Notice of Allowance), China, Russia, Japan, Australia, New Zealand, South Africa, India, New Zealand, Canada, South Korea, Mexico and Israel) and is being processed in other relevant markets. The Film patent is owned by Uppsalagruppen AB with an exclusive, eternal, free of charge license to Karessa in the therapeutic area of erectile dysfunction.
Karessa's European patent application was registered with the patent application number 17208875.9.
FOR MORE INFORMATION, PLEASE CONTACT:
Michael Brobjer, CEO, Karessa Pharma Holding AB (publ)
Tel: +46 8-768 22 33
About Karessa Pharma Holding AB
Karessa develops new pharmaceuticals based on a patented drug delivery technology and proven pharmaceutical substances in order to offer men with impotence problems a fast and more reliable effect. Karessa is listed on Nasdaq First North and has Remium as Certified Advisor.
About Karessa's pharmaceutical projects for treatment of erectile dysfunction
Current treatment of impotence is well proven and has a favorable safety profile, but many patients are bothered by the delayed onset and that it may vary depending on food intake. These problems are a consequence of the drug being given as tablets and thus has to pass the stomach and liver before reaching the right place in the body.
Karessa has developed a buccal film with Vardenafil (K-03). The film is small and is placed on the inside of the chin where it dissolves as the drug is delivered directly into the bloodstream via the oral mucosa. By this way the drug is delivered into the body and a quick and reliable onset is achieved. This completely regardless of whether you just have been eaten a good dinner.
Impotence affects many middle-aged men and has an increased prevalence of age. The global market for impotence drugs is estimated to a value of approximately SEK 40 billion.
For more information, please visit karessa.se